TABLE 2.
Drug susceptibility results obtained with a macrodilution series and the CLSI agar proportion method and then analyzed by the checkerboard method with M. tuberculosis
| Treatment | Methoda | MIC (μg/ml)/FIC (μg/ml)/FICIb |
|||
|---|---|---|---|---|---|
| Vancomycin | THL | Simvastatin | Fenofibrate | ||
| Alone | MS | 100/–/– | 50/–/– | 100/–/– | –/–/– |
| CLSI | 40/–/– | 5/–/– | 100/–/– | >200/–/– | |
| + 1 μg/ml THL | MS | 25/0.25/0.31 | –/–/– | –/–/– | –/–/– |
| CLSI | 10/0.25/0.375 | –/–/– | –/–/– | –/–/– | |
| + 25 μg/ml simvastatin | MS | 100/1/1.5 | –/–/– | –/–/– | –/–/– |
| CLSI | 20/0.5/1 | –/–/– | –/–/– | –/–/– | |
| + 50 μg/ml fenofibrate | MS | –/–/– | –/–/– | –/–/– | –/–/– |
| CLSI | 40/1/2 | –/–/– | –/–/– | –/–/– | |
| + 10 μg/ml vancomycin | MS | –/–/– | 3.1/0.06/0.31 | 50/0.5/1.5 | –/–/– |
| CLSI | –/–/– | –/–/– | –/–/– | –/–/– | |
| + 2 μg/ml vancomycin | MS | –/–/– | –/–/– | –/–/– | –/–/– |
| CLSI | –/–/– | 0.625/0.125/0.375 | 50/0.5/1 | >200/1/2 | |
a
MS, macrodilution series; CLSI, agar proportion method.
b
–, not applicable.